A team led by researchers at Fulcrum Therapeutics has developed new methods to measure the FMRP protein in blood…
Articles by Marisa Wexler, MS
Nova Mentis, a Canadian biotechnology company, is teaming up with KGK Science to develop Nova’s portfolio of therapies based on…
Zygel, an experimental cannabidiol gel that Zynerba Pharmaceuticals is developing to help normalize behaviors in people with fragile…
Note: This story was updated Aug. 12, 2022, to reflect that blarcamesine is an experimental activator. Treatment with Anavex2-73 (blarcamesine)…
Synaptogenix and Nemours A.I. DuPont Hospital for Children have signed an agreement to collaborate on a clinical trial…
A $90,000 grant from the FRAXA Research Foundation will fund a preclinical study that aims to assess the potential…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…
As early as 12 months of age, children with fragile X syndrome (FXS) display signs of social anxiety, a study…
The anticonvulsant carbamazepine can normalize behavior and memory in a mouse model of fragile X syndrome (FXS), suggesting…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops…